Characteristic | Total (N = 124) | AKI (n = 85) | Non-AKI (n = 39) |
---|---|---|---|
Median age, (range), years | 60 (30–74) | 60 (30–71) | 59 (41–74) |
Male | 97 (78) | 67 (79) | 30 (77) |
ECOG performance status | |||
 0 | 41 (33) | 26 (31) | 15 (38) |
 1 | 76 (61) | 55 (65) | 21 (54) |
 2 | 6 (5) | 3 (4) | 3 (8) |
 Not specified | 1 (1) | 1 (1) | |
 Hypertension | 25 (20) | 20 (24) | 5 (13) |
 Diabetes mellitus | 9 (7) | 7 (8) | 2 (5) |
 Cognitive impairment | 8 (6) | 4 (5) | 4 (10) |
CCI | |||
 0–1 | 92 (74) | 61 (72) | 31 (79) |
 2–3 | 32 (26) | 24 (28) | 8 (21) |
Smoking | |||
  ≥ 10 pack-years | 92 (74) | 65 (76) | 27 (69) |
Alcohol | |||
  ≥ 14 Units/week | 46 (37) | 35 (41) | 11 (28) |
 Number of nephrotoxic co-medications, median (range) | 2 (0–3) | 2 (0–3) | 2 (1–3) |
 Mean SCr (SD), μmol/l | 66 (12) | 66 (12) | 65 (12) |
Primary site | |||
 Oral cavity / oropharynx | 88 (71) | 58 (68) | 30 (77) |
 Hypopharynx | 15 (12) | 12 (14) | 3 (8) |
 Larynx | 17 (14) | 12 (14) | 5 (13) |
 Other | 4 (3) | 3 (4) | 1 (3) |
Tumor stage | |||
 T1–2 | 46 (37) | 29 (34) | 17 (44) |
 T3–4 | 69 (56) | 51 (60) | 18 (46) |
 Unknown | 6 (5) | 5 (6) | 1 (3) |
Nodal stage | |||
 N0 | 15 (12) | 12 (14) | 3 (8) |
 N+ | 106 (85) | 71 (84) | 35 (90) |
 Unknown | 3 (2) | 2 (2) | 1 (3) |